Tecomet and Orchid Orthopedic Solutions Complete Merger to Form Global Manufacturing Leader

Tecomet, owned by Charlesbank Capital Partners since 2017, and Orchid Orthopedic Solutions, backed by Nordic Capital since January 2019, have completed their merger as of May 14, 2026, consolidating their operations under the Tecomet brand. This strategic combination establishes a larger global manufacturing partner focused on serving customers in the Medical Technology (MedTech) and Aerospace & Defense industries. The transaction marks a significant milestone in MedTech contract manufacturing consolidation, bringing together two PE-backed platforms under a unified brand with expanded global scale.

The transaction, whose financial terms were not disclosed, merges Tecomet’s and Orchid’s complementary manufacturing capabilities. The combined company will offer an expanded portfolio including precision machining, additive manufacturing, forging, casting, and advanced finishing. This integration aims to provide customers with enhanced support across the entire product lifecycle — from initial development through full-scale production — with improved speed, flexibility, and supply chain resilience.

Tecomet, headquartered in Woburn, Massachusetts, operates 14 manufacturing facilities across five countries. It serves the Medical Device and Aerospace & Defense markets with services such as forging, casting, precision machining, photochemical etching, finishing, additive manufacturing, and sterile packaging. Orchid Orthopedic Solutions, based in Holt, Michigan, specialises in manufacturing services for MedTech original equipment manufacturers (OEMs). Orchid’s expertise includes additive manufacturing, bone in-growth coatings, forging, casting, and machining, focusing on implants, instruments, and technologies for joint reconstruction, hips, knees, spine, trauma, extremities, and dental markets. Orchid operates 10 facilities across the US, the UK, and Switzerland. Together, the combined entity operates 24 manufacturing facilities across North America, Europe, and beyond — one of the most comprehensive contract manufacturing footprints in the global MedTech sector.

Andreas Weller, CEO of Tecomet, has been appointed CEO of the combined company. He emphasised that the merger is designed to build a platform capable of meeting increasing customer demands with greater precision and reliability. “This combination is about more than scale. It is about building a platform that can meet the increasing complexity and demands of our customers with greater precision, reliability, and speed,” Weller said. “We are bringing together capabilities that are highly complementary to create a more complete and resilient manufacturing partner.”

The integration process will prioritise operational continuity, maintaining safety, quality, regulatory compliance, and on-time delivery across all sites. Dedicated integration teams will work to minimise disruption and ensure a seamless transition for customers. The phased approach to integration will align capabilities and operations while preserving service levels.

Strategically, the merger enhances the combined company’s ability to cross-sell expanded manufacturing services to a broader customer base across MedTech and Aerospace sectors. It also consolidates manufacturing facilities and supply chains, streamlines procurement, and reduces overhead through shared services. Operational improvements include faster production cycles, increased flexibility, and a more resilient global supply chain.

Market analysts note that this merger strengthens Tecomet’s position as a leading global manufacturing partner, expanding its geographic footprint across North America, Europe, and Asia-Pacific. The combined entity is well-positioned to invest in advanced manufacturing technologies, automation, and operational excellence, supporting long-term growth and innovation for its OEM customers.

Challenges remain in integrating diverse manufacturing processes, aligning corporate cultures, and managing regulatory complexities across multiple jurisdictions. However, the company’s leadership expresses confidence in realising synergies and delivering enhanced value to customers.

Looking ahead, the combined Tecomet aims to leverage its expanded technical expertise and global scale to pursue larger, more complex contracts and drive innovation in manufacturing solutions. The merger signals an acceleration of consolidation trends within the MedTech and Aerospace manufacturing sectors, potentially prompting competitors to enhance their capabilities or seek strategic partnerships.